GenScript ProBio and AbTis Enter into an Exclusive Worldwide License Agreement for ADC Targeting Claudin 18.2
On December 8th, 2021, GenScript ProBio entered into a partnership with AbTis, a Korean biotechnology company dedicated to the development of antibody drug conjugate (“ADC”), to grant AbTis an exclusive, worldwide license of GenScript ProBio’s anti-Claudin 18.2 monoclonal antibody (“Licensed Antibody”), to develop and commercialize the ADC. AbTis and GenScript ProBio will enter into an exclusive CDMO collaboration for the preclinical CMC development as well as clinical and commercial production of the antibodies for ADC product.
Claudin-18 is an important member of Claudin protein family, and Claudin18.2 is mainly expressed in gastric epithelial cells and highly expressed in primary malignant tumors, such as gastric, pancreatic, breast, colon and liver cancers. Claudin18.2 is now one of the most popular targets for pharmaceutical companies, especially those engaged in ADC development. GenScript ProBio team has completed antibody discovery, functional validation and cell line development for this Licensed Antibody. AbTis will continue to develop and commercialize ADC products based on the Licensed Antibody. Financial terms of the License Agreement were not disclosed.
About AbTis Antibody Technology
AbTis is a biotechnology company that specializes in antibody-drug conjugates (ADC) platform technology with its own proprietary patents and its own pipelines in developments in oncology areas.
More information: https://www.abtis.co.kr
About GenScript ProBio
GenScript ProBio is the biologics CDMO segment of GenScript Biotech, proactively providing end-to-end service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in antibody drug and gene and cell therapy to accelerate drug development for customers.
More information: https://www.genscriptprobio.com